Kayaalp Cuneyt, Ertugrul Ismail, Tolan Kerem, Sumer Fatih
Cuneyt Kayaalp, Ismail Ertugrul, Kerem Tolan, Fatih Sumer, Department of Gastrointestinal Surgery, Inonu University, 44280 Malatya, Turkey.
World J Gastrointest Surg. 2016 Mar 27;8(3):266-73. doi: 10.4240/wjgs.v8.i3.266.
To review the current data about the success rates of fibrin sealant use in pilonidal disease.
Fibrin sealant can be used for different purposes in pilonidal sinus treatment, such as filling in the sinus tracts, covering the open wound after excision and lay-open treatment, or obliterating the subcutaneous dead space before skin closure. We searched Pubmed, Google-Scholar, Ebsco-Host, clinicaltrials, and Cochrane databases and found nine studies eligible for analysis; these studies included a total of 217 patients (84% male, mean age 24.2 ± 7.8).
In cases where fibrin sealant was used to obliterate the subcutaneous dead space, there was no reduction in wound complication rates (9.8% vs 14.6%, P = 0.48). In cases where sealant was used to cover the laid-open area, the wound healing time and patient comfort were reported better than in previous studies (mean 17 d, 88% satisfaction). When fibrin sealant was used to fill the sinus tracts, the recurrence rate was around 20%, despite the highly selected grouping of patients.
Consequently, using fibrin sealant to decrease the risk of seroma formation was determined to be an ineffective course of action. It was not advisable to fill the sinus tracts with fibrin sealant because it was not superior to other cost-effective and minimally invasive treatments. New comparative studies can be conducted to confirm the results of sealant use in covering the laid-open area.
回顾目前关于纤维蛋白封闭剂用于藏毛疾病成功率的相关数据。
纤维蛋白封闭剂在藏毛窦治疗中可用于不同目的,如填充窦道、覆盖切除和敞开式治疗后的开放伤口,或在皮肤闭合前消除皮下死腔。我们检索了PubMed、谷歌学术、Ebsco-Host、临床试验和Cochrane数据库,发现9项研究符合分析条件;这些研究共纳入217例患者(84%为男性,平均年龄24.2±7.8岁)。
在使用纤维蛋白封闭剂消除皮下死腔的病例中,伤口并发症发生率没有降低(9.8%对14.6%,P=0.48)。在使用封闭剂覆盖敞开区域的病例中,据报道伤口愈合时间和患者舒适度优于以往研究(平均17天,满意度88%)。当使用纤维蛋白封闭剂填充窦道时,尽管患者经过高度筛选分组,复发率仍约为20%。
因此,使用纤维蛋白封闭剂降低血清肿形成风险被确定为无效的治疗方法。用纤维蛋白封闭剂填充窦道不可取,因为它并不优于其他经济有效且微创的治疗方法。可以进行新的对比研究以证实封闭剂用于覆盖敞开区域的效果。